Thiazolidinediones and Bone: A Review of Recent Clinical Evidence
Author Information
Author(s): Ann V. Schwartz
Primary Institution: University of California San Francisco
Hypothesis
Reduced bone formation resulting from activation of peroxisome proliferator-activated receptor-γ (PPARγ) is a central mechanism for TZDs' effect on bone.
Conclusion
The study found that thiazolidinediones increase fracture risk and bone loss, particularly in women.
Supporting Evidence
- Both rosiglitazone and pioglitazone were linked to increased fracture risk among diabetic women.
- Short-term clinical trials showed substantial bone loss in women treated with TZDs.
- Observational studies indicated increased bone loss in diabetic women using TZDs.
Takeaway
This study shows that certain diabetes medications can make bones weaker and increase the chance of breaking them, especially in women.
Methodology
The review analyzed clinical trial data and observational studies regarding the effects of TZDs on bone health.
Potential Biases
Potential bias due to reliance on adverse event reports rather than planned outcomes in clinical trials.
Limitations
The review is based on limited clinical trial data and observational studies, which may not capture all relevant factors.
Participant Demographics
The study included 2511 men and 1840 women, with an average age of 57 years; 77% of women were postmenopausal.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 1.17, 2.80
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website